vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $71.1M, roughly 1.2× RE/MAX Holdings, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 2.0%, a 20.8% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -1.8%). RE/MAX Holdings, Inc. produced more free cash flow last quarter ($33.5M vs $28.5M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -4.7%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.
FDMT vs RMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $71.1M |
| Net Profit | $19.4M | $1.4M |
| Gross Margin | — | — |
| Operating Margin | 17.3% | 13.1% |
| Net Margin | 22.8% | 2.0% |
| Revenue YoY | 8508900.0% | -1.8% |
| Net Profit YoY | 139.1% | -75.2% |
| EPS (diluted) | $0.43 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $71.1M | ||
| Q3 25 | $90.0K | $73.2M | ||
| Q2 25 | $15.0K | $72.8M | ||
| Q1 25 | $14.0K | $74.5M | ||
| Q4 24 | $1.0K | $72.5M | ||
| Q3 24 | $3.0K | $78.5M | ||
| Q2 24 | $5.0K | $78.5M | ||
| Q1 24 | $28.0K | $78.3M |
| Q4 25 | $19.4M | $1.4M | ||
| Q3 25 | $-56.9M | $4.0M | ||
| Q2 25 | $-54.7M | $4.7M | ||
| Q1 25 | $-48.0M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $-43.8M | $966.0K | ||
| Q2 24 | $-35.0M | $3.7M | ||
| Q1 24 | $-32.4M | $-3.4M |
| Q4 25 | 17.3% | 13.1% | ||
| Q3 25 | -67983.3% | 25.0% | ||
| Q2 25 | -396373.3% | 19.3% | ||
| Q1 25 | -383007.1% | 7.2% | ||
| Q4 24 | — | 5.9% | ||
| Q3 24 | -1704400.0% | 19.4% | ||
| Q2 24 | -849120.0% | 20.6% | ||
| Q1 24 | -136200.0% | 5.8% |
| Q4 25 | 22.8% | 2.0% | ||
| Q3 25 | -63195.6% | 5.4% | ||
| Q2 25 | -364386.7% | 6.4% | ||
| Q1 25 | -342657.1% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | -1461433.3% | 1.2% | ||
| Q2 24 | -699060.0% | 4.7% | ||
| Q1 24 | -115717.9% | -4.3% |
| Q4 25 | $0.43 | — | ||
| Q3 25 | $-1.01 | — | ||
| Q2 25 | $-0.98 | — | ||
| Q1 25 | $-0.86 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.79 | — | ||
| Q2 24 | $-0.63 | — | ||
| Q1 24 | $-0.66 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $118.7M |
| Total DebtLower is stronger | — | $432.2M |
| Stockholders' EquityBook value | $505.7M | $452.4M |
| Total Assets | $566.7M | $582.5M |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $118.7M | ||
| Q3 25 | $305.1M | $107.5M | ||
| Q2 25 | $293.2M | $94.3M | ||
| Q1 25 | $321.4M | $89.1M | ||
| Q4 24 | $424.9M | $96.6M | ||
| Q3 24 | $501.9M | $83.8M | ||
| Q2 24 | $541.9M | $66.1M | ||
| Q1 24 | $525.9M | $82.1M |
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
| Q4 25 | $505.7M | $452.4M | ||
| Q3 25 | $369.0M | $448.1M | ||
| Q2 25 | $420.9M | $442.4M | ||
| Q1 25 | $469.7M | $433.5M | ||
| Q4 24 | $510.6M | $429.5M | ||
| Q3 24 | $552.9M | $423.1M | ||
| Q2 24 | $588.3M | $418.4M | ||
| Q1 24 | $600.6M | $412.0M |
| Q4 25 | $566.7M | $582.5M | ||
| Q3 25 | $424.0M | $582.2M | ||
| Q2 25 | $473.6M | $574.8M | ||
| Q1 25 | $515.7M | $571.4M | ||
| Q4 24 | $560.4M | $581.6M | ||
| Q3 24 | $604.0M | $578.6M | ||
| Q2 24 | $620.1M | $571.4M | ||
| Q1 24 | $629.9M | $566.7M |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $40.9M |
| Free Cash FlowOCF − Capex | $28.5M | $33.5M |
| FCF MarginFCF / Revenue | 33.5% | 47.1% |
| Capex IntensityCapex / Revenue | 0.1% | 10.4% |
| Cash ConversionOCF / Net Profit | 1.47× | 28.39× |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $56.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $40.9M | ||
| Q3 25 | $-46.5M | $17.7M | ||
| Q2 25 | $-43.4M | $4.6M | ||
| Q1 25 | $-47.8M | $5.7M | ||
| Q4 24 | $-134.6M | $59.7M | ||
| Q3 24 | $-29.4M | $17.6M | ||
| Q2 24 | $-30.2M | $15.9M | ||
| Q1 24 | $-29.1M | $9.4M |
| Q4 25 | $28.5M | $33.5M | ||
| Q3 25 | $-46.6M | $16.4M | ||
| Q2 25 | $-43.4M | $2.9M | ||
| Q1 25 | $-48.4M | $4.0M | ||
| Q4 24 | $-138.4M | $53.0M | ||
| Q3 24 | $-31.2M | $16.3M | ||
| Q2 24 | $-30.6M | $14.0M | ||
| Q1 24 | $-29.8M | $6.8M |
| Q4 25 | 33.5% | 47.1% | ||
| Q3 25 | -51765.6% | 22.4% | ||
| Q2 25 | -289620.0% | 4.0% | ||
| Q1 25 | -345635.7% | 5.3% | ||
| Q4 24 | -13837100.0% | 73.2% | ||
| Q3 24 | -1038966.7% | 20.8% | ||
| Q2 24 | -611840.0% | 17.8% | ||
| Q1 24 | -106421.4% | 8.6% |
| Q4 25 | 0.1% | 10.4% | ||
| Q3 25 | 101.1% | 1.8% | ||
| Q2 25 | 440.0% | 2.2% | ||
| Q1 25 | 4507.1% | 2.3% | ||
| Q4 24 | 378600.0% | 9.1% | ||
| Q3 24 | 59266.7% | 1.7% | ||
| Q2 24 | 6980.0% | 2.4% | ||
| Q1 24 | 2535.7% | 3.3% |
| Q4 25 | 1.47× | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDMT
Segment breakdown not available.
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
